AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06790472 — intervention group
Intervention type: BEHAVIORAL
Intervention: Online Lifestyle Intervention
Description: The Metabolic Wellness Program (MWP) is an established 8-week program that provides participants with health education videos and webinars that focus on evidence-based nutrition, fitness, sleep, and stress intervention, including with CGM, allowing participants to monitor their real-time glucose data and to learn which lifestyle choices are best for their glycemic control and personal metabolic health. The program is also intended to help healthy participants maintain their metabolic health and lower their potential risk of developing cardiometabolic disease, as well as at-risk and pre-diabetic participants preventing the progression to T2D and people with established T2D reverse their condition.
Study NCT06790472 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring
Description: CGM measurements begin at enrollment with training provided digitally Participants will be asked to live life as usual whilst wearing the device with initial 10-14 day readings providing baseline data. Participants will participate in the online lifestyle program, which the investigators refer to as the intervention stage. Participants will also receive questionnaires on behavior change at the beginning of week 5. During the final two weeks of the program (weeks 7-8), the final 10-14 days of CGM will be used as comparison data with baseline information.
Study NCT06791148 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: 2Gy/f，q3w，×4f
Study NCT06791148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: 100-120mg/m2,i.v.,d2,d9,q3w
Study NCT06791148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: 20mg/kg, i.v., d2, q3w
Study NCT06792201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SARC-F, Handgrip test, Chair stand test
Description: The SARC-F questionnaire is a simple to use questionnaire consisting of five questions about daily actions.To test the force will be used: Hand-grip test and Chair stand test. The tool used for the hand-grip test is the GRIP-A (Takei). The test is performed on the dominant limb and repeated three times. The position taken by the patient will be: sitting with shoulders and elbows flexed, forearms in neutral position. The Chair stand test measures the time it takes for a patient to get up five times from a sitting position without the help of her upper limbs. The test will be timed.The measurement of lean mass will be carried out by means of a bio impedance meter. This instrument does not measure muscle mass directly but estimates it based on the electrical conductivity of the whole body. Bioimpedance is a method that is easy and safe for the patient to use.
Study NCT06792604 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Anal self-sampling (smear)
Description: Anal self-sampling (smear) at M12, M24 and M36 (each year) for HPV16+ patients at M0 and anal self-sampling (smear) at M36 for HPV16- at M0
Study NCT06792604 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HPV questionnaire
Description: HPV questionnaire at each visit M0, M12, M24 and M36 for HPV16-positive patients at M0 and HPV questionnaire at each visit M0, 4 and M36 for HPV16-negative patients
Study NCT04782258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan Suspension
Description: Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age.
Study NCT04782258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan Tablets
Description: Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
Study NCT06636500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG001419
Description: Oral doses
Study NCT06636500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses
Study NCT06790953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group- A Conventional Sensed Mouth Wash
Description: In Group- A Conventional Sensed Mouth Wash will be used for treatment of Dentin hypersensitivity.~Visual Analogue scoring system will be used to calculate the dentin hypersensitivity.
Study NCT06790953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group-B Novel Titania nanoparticles enriched Mouth Wash
Description: In Group-B Novel Titania nanoparticles enriched Mouth wash will be used to treat the Dentin hypersensitivity.~Visual Analogue scoring system will be used to calculate the dentin hypersensitivity.
Study NCT04720339 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Molecular monitoring by quantification of cell-free DNA
Description: Molecular monitoring by quantification of cell-free DNA (absolute value and variation from baseline) of two house-keeping genes (RPP30, TMEM11) by droplet digital PCR, during based-immunotherapy treatments of NSCLC patients.~Cell-free DNA will be extracted from 4 ml of plasma before treatments by immunotherapy, obtained from blood Streck® tubes.~Quantification of house-keeping genes (or mutated genes if some are previously routinely identified in tumor tissue) by ddPCR.
Study NCT05480241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatic Enzyme Replacement Therapy
Description: Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
Study NCT05480241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + Omeprazole 20mg once daily on fasting
Study NCT05704842 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises.
Study NCT04971369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-NY001
Description: 89Zr-NY001 injection followed by 89Zr-NY001 PET scan
Study NCT06472453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allograft/Xenograft
Description: Alveolar ridge preservation of a single extraction socket site with a mixture of demineralized cortical bone substitute vallos® and xenograft Bio-Oss®.
Study NCT06472453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: Alveolar ridge preservation of a single extraction socket site with vallos® (mineralized cortico-cancellous bone substitute)
Study NCT05419947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERDYE powder for solution for injection 25 mg
Description: Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.
Study NCT05719077 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EDITH-HC
Description: This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.
Study NCT05719077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDITH-HC
Description: This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.
Study NCT06423170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus GEMOX
Description: 1. Camrelizumab：200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : oxaliplatin 100mg/m2，D1, gemcitabine1000mg/m2，D1，intravenous infusion.~3. Carrilizumab and GEMOX chemotherapy will be intravenous infused atone day. Three weeks is a course of treatment,a total of 6-8 courses.
Study NCT06274268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sarcopenia diagnostic test
Description: the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.
Study NCT06361420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Driving pressure-guided positive end expiratory pressure
Description: The positive end expiratory pressure setting rules are as follows: a 10-cycle experimental ventilation will be carried out at each level of positive end expiratory pressure after intubation, and the driving pressure of the last cycle will be recorded. The positive end expiratory pressure value corresponding to the lowest driving pressure is recognised as the optimal ventilation parameter. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
Study NCT06361420 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optimal oxygenation-guided positive end expiratory pressure
Description: Positive end expiratory pressure will be maintained at the level facilitating optimal oxygenation during the off-pump period. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
Study NCT06361420 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ventilation strategy
Description: A Pressure regulated volume control mode is used in the patients before extubation. The ventilation target are: (1) a pulse oximetry ≥ 90% or a partial pressure of arterial oxygen ≥ 60mm Hg; (2) a partial pressure of arterial carbon dioxide: 35 \~ 50 mm Hg and (3) a pondus hydrogenii (pH) value > 7.20. The ventilation parameters are: (1) tidal volume: 6 \~ 8 mL/Kg predictive body weight; (2) respiratory rate 10 \~ 15 cycles per minute; (3) inspiratory/expiratory ratio: 1:1.5 (1:2.5 - 1:3 in the patients with chronic obstructive pulmonary disease); positive end expiratory pressure: 0 \~ 8 cm centimeter water column. On-pump ventilation parameters are: (1) tidal volume: 4 mL/Kg predictive body weight; (2) respiratory rate: 4 circles per minute; (3) positive end-expiratory pressure: 4 cm centimeter water column; (4) inspiratory oxygen fraction: 21%.
Study NCT06361420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation strategy
Description: A Pressure regulated volume control mode is used in the patients before extubation. The ventilation target are: (1) a pulse oximetry ≥ 90% or a partial pressure of arterial oxygen ≥ 60mm Hg; (2) a partial pressure of arterial carbon dioxide: 35 \~ 50 mm Hg and (3) a pondus hydrogenii (pH) value > 7.20. The ventilation parameters are: (1) tidal volume: 6 \~ 8 mL/Kg predictive body weight; (2) respiratory rate 10 \~ 15 cycles per minute; (3) inspiratory/expiratory ratio: 1:1.5 (1:2.5 - 1:3 in the patients with chronic obstructive pulmonary disease); positive end expiratory pressure: 0 \~ 8 cm centimeter water column. On-pump ventilation parameters are: (1) tidal volume: 4 mL/Kg predictive body weight; (2) respiratory rate: 4 circles per minute; (3) positive end-expiratory pressure: 4 cm centimeter water column; (4) inspiratory oxygen fraction: 21%.
Study NCT06361420 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Management of hypoxemia
Description: Management of hypoxemia will be initiated immediately through the following steps: (1) carefully checking anaesthesia apparatus malfunction, airway normality, and monitoring accuracy; (2) improving cardiac function, correcting fluid overload, and alleviating systemic inflammation; (3) performing alveolar recruitment manoeuvres as described above; (4) increasing the tidal volume and positive end expiratory pressure within the upper limits; (5) increasing the respiratory rate while addressing concurrent hypercapnia; (6) titrating the fraction of inspiratory oxygen until the pulse oximetry reaches or exceeds 90%; and (7) considering the use of extracorporeal membrane oxygenation if any following situations occurred 14: (a) a partial pressure of arterial oxygen \< 50 mm Hg for more than 3 hours; (b) a partial pressure of arterial oxygen to inspiratory oxygen fraction ratio \< 80 mm Hg for more than 6 hours; or (c) a critical respiratory acidosis for more than 6 hours.
Study NCT06361420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of hypoxemia
Description: Management of hypoxemia will be initiated immediately through the following steps: (1) carefully checking anaesthesia apparatus malfunction, airway normality, and monitoring accuracy; (2) improving cardiac function, correcting fluid overload, and alleviating systemic inflammation; (3) performing alveolar recruitment manoeuvres as described above; (4) increasing the tidal volume and positive end expiratory pressure within the upper limits; (5) increasing the respiratory rate while addressing concurrent hypercapnia; (6) titrating the fraction of inspiratory oxygen until the pulse oximetry reaches or exceeds 90%; and (7) considering the use of extracorporeal membrane oxygenation if any following situations occurred 14: (a) a partial pressure of arterial oxygen \< 50 mm Hg for more than 3 hours; (b) a partial pressure of arterial oxygen to inspiratory oxygen fraction ratio \< 80 mm Hg for more than 6 hours; or (c) a critical respiratory acidosis for more than 6 hours.
Study NCT04965116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestin Only Contraceptive Pills
Description: Daily pill (placebo or active tablet)
Study NCT04965116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progestin Only Contraceptive Pills
Description: Daily pill (placebo or active tablet)
Study NCT06386536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intelligent stationary bike
Description: A stationary motorized bike prototype that can evaluate lower limb functions such as strength, coordination, range of motion, and tonus. Based on the evaluation results, the iBike proposes a training program that is specific to each individual needs. Moreover, the intelligent bike offers diverse pedaling modes such as forward and backward pedaling, assisted pedaling, isotonic pedaling and pedaling with sensory stimulations.
Study NCT06386536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent stationary bike
Description: A stationary motorized bike prototype that can evaluate lower limb functions such as strength, coordination, range of motion, and tonus. Based on the evaluation results, the iBike proposes a training program that is specific to each individual needs. Moreover, the intelligent bike offers diverse pedaling modes such as forward and backward pedaling, assisted pedaling, isotonic pedaling and pedaling with sensory stimulations.
Study NCT06386536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional stationary bilke
Description: A conventional stationary bike that can be found in gyms or rehab centers.
Study NCT06386536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional stationary bilke
Description: A conventional stationary bike that can be found in gyms or rehab centers.
Study NCT04571476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrathin bronchoscope
Description: Ultrathin bronchoscope (UTB) with an outer diameter no more than 3.0-mm and a 1.7-mm working channel.
Study NCT04571476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thin bronchoscope
Description: Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel.
Study NCT04571476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual bronchoscopic navigation combined with endobronchial ultrasound
Description: VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.
Study NCT04571476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual bronchoscopic navigation combined with endobronchial ultrasound
Description: VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.
Study NCT06384651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraosseous Vancomycin Injection
Description: * IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* IO Injection will take place into the medial malleolus.
Study NCT06384651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Vancomycin
Description: • Patients will receive the orthopedic surgeon's standard of care pre-operative antibiotic regimen for TAA patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL normal saline (NS))
Study NCT04571476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guide sheath
Description: GS is a cannula with the thinnest outer diameter of 1.95 mm.
Study NCT05191849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample collection
Description: Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2\~4 cycles of chemotherapy, or at the time of disease progression.
Study NCT04496960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: XELJANZ(R) is the citrate salt of tofacitinib. Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo \[2,3-d\]pyrimidin-4-ylamino) -beta-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) It is freely soluble in water and has a molecular weight of 504.5 Daltons. XELJANZ(R) is supplied for oral administration as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) white round, immediate-release film-coated tablet. Each tablet of XELJANZ(R) contains the appropriate amount of XELJANZ(R) as a citrate salt and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6cP, titanium dioxide, macrogol/PEG3350, and triacetin.
Study NCT04496960 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: white, round, film-coated tablet
Study NCT05777031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum (CCH)
Description: Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
Study NCT06527586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft contact lens
Description: Vision Correction
Study NCT06527586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft contact lens
Description: Vision Correction
Study NCT04916236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-4630
Description: * SHP2-inhibitor~* Powder in capsule~* Administered on day 1 and day 2 of every week
Study NCT04916236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: * ERK inhibitor~* Powder in capsule~* Administered every day
Study NCT05929066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC
Study NCT05446805 — intervention group
Intervention type: DRUG
Intervention: F 18 AV-1451 (Flortaucipir)
Description: A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
Study NCT05446805 — intervention group
Intervention type: DRUG
Intervention: [11C]-Pittsburgh Compound B ([11C]PiB)
Description: A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
Study NCT05201703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fycompa
Description: Fycompa 4 mg daily
Study NCT05201703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fycompa with a boost
Description: Fycompa 4 mg daily with a boost to 6 mg daily a week before the start of your menstruation cycle until Day 4 of your cycle.